Hudson Bay Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Hudson Bay Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27,670	Closed	-$1.33M	–	1530
2026 Q1	$1.33M	Buy	+27,670	New	+$1.23M	﹤0.01%	834
2025 Q3	–	Sell	-70,780	Closed	-$1.96M	–	1466
2025 Q2	$1.96M	Sell	70,780 -129,220	-65%	-$3.29M	0.01%	805
2025 Q1	$4.44M	Sell	200,000 -25,000	-11%	-$515K	0.01%	623
2024 Q4	$4.45M	Buy	225,000 +135,000	+150%	+$3.08M	0.02%	523
2024 Q3	$2.25M	Sell	90,000 -165,000	-65%	-$4.02M	0.01%	555
2024 Q2	$4.76M	Buy	255,000 +104,000	+69%	+$1.95M	0.02%	385
2024 Q1	$2.98M	Sell	151,000 -64,000	-30%	-$1.25M	0.02%	400
2023 Q4	$3.77M	Sell	215,000 -87,500	-29%	-$1.44M	0.02%	348
2023 Q3	$5.25M	Sell	302,500 -377,500	-56%	-$6.36M	0.04%	276
2023 Q2	$9.57M	Sell	680,000 -180,200	-21%	-$2.41M	0.07%	182
2023 Q1	$9.26M	Buy	860,200 +260,200	+43%	+$3.43M	0.08%	180
2022 Q4	$8.99M	Sell	600,000 -600,000	-50%	-$8.74M	0.09%	202
2022 Q3	$15.4M	Sell	1,200,000 -175,000	-13%	-$1.99M	0.14%	98
2022 Q2	$13.3M	Buy	1,375,000 +95,000	+7%	+$886K	0.1%	135
2022 Q1	$12.7M	Buy	1,280,000 +230,000	+22%	+$2.44M	0.17%	94
2021 Q4	$12.4M	Sell	1,050,000 -100,000	-9%	-$1.23M	0.13%	99
2021 Q3	$13.1M	Buy	1,150,000 +350,000	+44%	+$4.56M	0.18%	85
2021 Q2	$11.1M	Buy	800,000 +305,000	+62%	+$4.63M	0.13%	109
2021 Q1	$9.16M	Sell	495,000 -105,000	-18%	-$2.15M	0.11%	133
2020 Q4	$10.6M	Buy	600,000 +150,000	+33%	+$2.63M	0.11%	112
2020 Q3	$6.89M	Buy	450,000 +265,000	+143%	+$4.98M	0.1%	180
2020 Q2	$4.71M	Sell	185,000 -45,000	-20%	-$940K	0.08%	203
2020 Q1	$3.56M	Sell	230,000 -210,000	-48%	-$3.29M	0.09%	199
2019 Q4	$4.87M	Buy	440,000 +310,000	+238%	+$2.69M	0.11%	177
2019 Q3	$1.11M	Buy	130,000 +15,000	+13%	+$166K	0.03%	305
2019 Q2	$1.56M	Buy	115,000 +25,000	+28%	+$388K	0.04%	297
2019 Q1	$1.63M	Buy	+90,000	New	+$1.74M	0.02%	496

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Hudson Bay Capital Management's KNSA Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 27,670 shares — an estimated $1.33M sold.

Hudson Bay Capital Management first reported a position in KNSA in Q1 2019 and held it in 27 quarters. The position peaked at $15.4M in Q3 2022. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Hudson Bay Capital Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Hudson Bay Capital Management sold 27,670 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.33M.
Hudson Bay Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2019 and held it in 27 quarters.
Hudson Bay Capital Management's Kiniksa Pharmaceuticals position peaked at $15.4M in Q3 2022.
267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.